Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical (Tianda). Upon completion of the acquisition, Simcere will start manufacturing Rosuvastatin.
Subscribe to our email newsletter
The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda.
Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related conditions.
Jinsheng Ren, chairman and CEO of Simcere, said: “We are delighted to join forces with Tianda to manufacture Rosuvastatin in China. We believe that we can help more heart disease patients in China benefit from this drug.”